Navigation Links
GeneTex Antibody Company to Launch a Line of New Zebrafish Primary Antibodies
Date:6/28/2011

IRVINE, Calif., June 28, 2011 /PRNewswire/ -- GeneTex, a leading manufacturer of high quality antibodies, is pleased to announce that they will be launching a full line of zebrafish antibodies.

Zebrafish have been increasingly utilized as a model organism for scientific research. Due to their short lifecycles and relatively large clutch sizes, they are a useful model for genetic studies. Zebrafish eggs are externally fertilized; therefore, researchers can control and manipulate the embryos from the moment of fertilization. In addition, their embryos are transparent, so researchers are able to observe the changes that occur throughout the developmental stages of the embryo.

"We believe the zebrafish is an excellent model organism for biological research," said Dr. Kristina Beiswenger, Product Specialist at GeneTex, "however, this field has long been overlooked and lacks quality antibody reagents. GeneTex is fully committed to developing high quality antibodies specifically validated with zebrafish samples. We will continue to expand this product line to satisfy the needs of zebrafish research."

Many zebrafish tissues and organ systems, including the kidney, pancreas, bones and heart, are comparable to those of higher mammals and humans. The relatively large size, large number and external development of zebrafish embryos make them especially agreeable to manipulation by a variety of chemical, physical and genetic methods.

GeneTex is launching one of the largest collections of zebrafish antibodies that are validated for western blotting, immunofluorescence (ICC/IF), immunohistochemistry (IHC) and other applications. Almost all of the antibodies in the line are antigen-affinity purified, which results in higher quality antibodies.

For additional information on GeneTex's full line of zebrafish antibodies, call toll-free 877-GENETEX (436-3839) or visit www.GeneTex.com/zebrafish.

About GeneTex:

GeneTex is an antibody company that was founded by scientists in 1997. They strive to produce the highest quality antibodies and reagents. Their primary antibodies and secondary antibodies are created through a process involving extensive research, development and validation.  GeneTex has over 35,000 primary antibodies in its catalog that are all backed by a 100% Satisfaction Guarantee.  


'/>"/>
SOURCE GeneTex
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
2. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
3. ESBATech Announces Successful Completion of Phase I Clinical Study for Lead Antibody Fragment in Ophthalmic Indications
4. Takeda San Francisco, Inc. Appoints Gregory Landes, Ph.D. Vice President of Antibody Research
5. Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration
6. SoluLinK Introduces New One-Shot ChromaLink(TM) Biotin Antibody Labeling Kit with Built-in Biotin Quantification.
7. Medarex and Massachusetts Biologic Laboratories Announce Primary Objective Achieved in Phase 2 Trial of Monoclonal Antibody Combination for the Treatment of Clostridium difficile Associated Diarrhea (CDAD)
8. InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement
9. PacificGMP and Actinium Pharmaceuticals Announce Agreements for cGMP Antibody Manufacturing and Stability Testing
10. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
11. BioWa Licenses POTELLIGENT(R) Technology to GlaxoSmithKline for Use in Antibody Development and Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... ... May 23, 2017 , ... Kathy Goin is joining ... She brings years of expertise in establishing and leading clinical operations at Sponsors ... licensed occupational therapist, through a variety of leadership roles in Clinical Operations, to ...
(Date:5/22/2017)... , ... May 22, 2017 , ... ... with other leaders of the Maryland Biohealth community in developing and issuing recommendations ... Top 3 U.S. BioHealth Innovation Hub by 2023. , The ...
(Date:5/19/2017)... ... May 19, 2017 , ... The University City Science Center ... ripe for commercialization, and who are affiliated with the 21 partner academic and ... QED, now in its tenth round, is the first multi-institutional proof-of-concept program for ...
(Date:5/18/2017)... ... 17, 2017 , ... DAACRO ... power by providing investigators access to a high-profile scientific advisory board. Today, ... advisory board. “We are committed to offering superior services and solutions for ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, a ... authentication solutions, today announced that it has been ... Research Projects Activity (IARPA) to develop next-generation Presentation ... "Innovation has been a driving force ... program will allow us to innovate and develop ...
(Date:4/6/2017)... 2017 Forecasts by Product Type ... by End-Use (Transportation & Logistics, Government & Public Sector, ... Fossil Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation ... Are you looking for a definitive report on the ... ...
(Date:4/4/2017)... --  EyeLock LLC , a leader of iris-based identity ... and Trademark Office (USPTO) has issued U.S. Patent No. ... iris image with a face image acquired in sequence ... th issued patent. "The issuance ... multi-modal biometric capabilities that have recently come to market ...
Breaking Biology News(10 mins):